Mounting evidence points to increased rates of cardiovascular disease (CVD) among people living with HIV/AIDS (PLWHA). Endothelial dysfunction (loss of endothelium-dependent vascular relaxation in response to provasodilatory stimuli) constitutes an early pathophysiological event in atherogenesis and CVD. Both HIV-1 infection and antiretroviral therapy (ART) are implicated in the development of endothelial dysfunction; however, conclusions are frequently drawn from associations shown in epidemiological studies. In this narrative review of mainly in vitro and animal studies, we report on the current understanding of how various HIV-1 proteins, HIV-1-induced proinflammatory cytokines and common antiretroviral drugs directly impact vascular endothelial cells. Proposed cellular mechanisms underlying the switch to a dysfunctional state are discussed, including oxidative stress, impaired expression and regulation of endothelial nitric oxide (NO) synthase (eNOS) and increased expression of vascular adhesion molecules. From the literature, it appears that increased reactive oxygen species (ROS) production, linked to decreased NO bioavailability and ensuing endothelial dysfunction, may be proposed as a putative final common pathway afflicting the vascular endothelium in PLWHA. The HIV-1-proteins Tat, Gp120 and Nef in particular, the proinflammatory cytokine, TNF-a, and the antiretroviral drugs Efavirenz and Lopinavir, most commonly postulated to be primary causal agents of endothelial dysfunction, are also discussed. We conclude that, despite existing evidence from basic research papers, a significant gap remains in terms of the exact
Introduction
Mounting evidence is pointing to an association between the infective human immunodeficiency virus-1 (HIV-1) and noncommunicable cardiovascular disease (CVD). A meta-analysis by Islam et al. [1] found the relative risk of developing CVD in people living with HIV/AIDS (PLWHA) to be 61% higher than that of the HIV uninfected population. Furthermore, the same study showed that the cardiovascular risk in PLWHA receiving highly active antiretroviral therapy (HAART) was twice that of HIV-positive individuals who were treatment-na€ ıve. The United Nations AIDS update indicates that in 2015, 17.0 million people worldwide were living with HIV and receiving antiretroviral therapy [2] . Therefore, considering the sheer prodigiousness of this global pandemic and the troubling data on its comorbidity with CVD, zooming in on HIV's intersection with antiretroviral therapy and cardiovascular health is consequently imperative, as we have previously emphasised [3] .
Endothelial dysfunction is regarded as one of the first pathophysiological events in the development of atherosclerosis and subsequent CVD [4] , with HIV-1-induced proinflammatory cytokines, HIV-1 proteins and antiretroviral drugs all implicated in its development [5] . A better understanding of the link between HIV-infection and endothelial dysfunction, is therefore invaluable for researchers and clinicians alike and we are currently conducting a prospective cohort study investigating whether HIV-infection with and without antiretroviral therapy (ART) exerts changes to vascular endothelial function as measured by flow-mediated dilation (FMD) of the brachial artery [6] . Given the vastness and complexity of this topic, and the fact that multiple, interacting cellular mechanisms and pathways are involved, integrating the literature available becomes a mammoth task. Although a number of review papers have been published on the interaction between HIV infection and endothelial dysfunction [5, [7] [8] [9] [10] [11] , few have integrated findings from in vitro, endothelial cell-based studies that account for both viral and treatment factors. In the present narrative review, we endeavour to address this paucity and elucidate the current understanding of how HIV-1-induced proinflammatory cytokines, various HIV-1 proteins and common antiretroviral drugs directly impact vascular endothelial cells, focusing in particular on in vitro and animal studies.
In our search, standard scientific search engines such as PubMed and Google Scholar were utilised entering keywords including: 'vascular endothelium', 'vascular endothelial cells', 'HIV' and 'endothelial dysfunction' in combination with the names of the individual HIV proteins, common antiretroviral drugs and proinflammatory cytokines that have previously been shown to be upregulated during HIV-1 infection [12] . Relevant studies focussing on in vitro investigations were included, and although a comprehensive review of epidemiological studies falls outside the scope of the present paper, findings from selected human/clinical studies were included with the aim to provide context.
The vascular endothelium and endothelial dysfunction
The vascular endothelium plays an important part in regulating vascular homoeostasis. It achieves this by responding to various physical and chemical signals via the production of a wide variety of factors that regulate vascular tone, cell adhesion, coagulation, smooth muscle cell proliferation and inflammation. One of the key agents in this regard is the gaseous free-radical, nitric oxide (NO), functioning to maintain the vascular wall in a homoeostatic state by opposing, among others, inflammation, cellular proliferation and thrombosis [13] . In endothelial cells, NO is constitutively synthesised by the dimeric enzyme endothelial nitric oxide synthase (eNOS) from the amino acid L-arginine, utilising oxygen and reduced nicotinamideadenine-dinucleotide phosphate (NADPH) as cosubstrates [14] . When vascular homoeostasis is disturbed beyond the regulating capabilities of the endothelium, the scale is consequently tipped from endothelial function to dysfunction, a scenario in which the modification of both NO and eNOS is pivotally implicated.
Endothelial dysfunction is defined as the loss of the endothelium's ability to induce vascular relaxation in response to provasodilatory stimuli such as shear stress [4] . Essentially, it represents a state where a reduction in NO bioavailability leads to a switch in cellular signalling, propelling the endothelium into an activated, proinflammatory state. A reduction in NO bioavailability, the consequence of a decrease in NO production and/or increased NO inactivation, is ascribed by most authors to oxidative stress. An increase in reactive oxygen species (ROS) contributes to the reduction in NO bioavailability in two ways: first, by reacting with NO and transforming it into a damaging reactive nitrogen species, peroxynitrite, and second, by uncoupling eNOS, and hence modifying it into a ROS producing enzyme [4, [13] [14] [15] . Circulating leucocytes are generally not adhesive to endothelial cells in a nonactivated state. The inflammatory response, characterised by the migration of leucocytes across endothelial cells, is dependent on adhesion molecules which facilitate this movement [16] and, under homoeostatic conditions, this is a normal process. However, in the case of endothelial dysfunction (which can perhaps be alternately termed nonhomoeostatic endothelial cell activation), this process becomes a maladaptive response. Endothelial dysfunction occurs at susceptible sites in the arterial vasculature where pro-atherogenic, low endothelial shear stress occurs. Endothelial shear stress is the frictional force exerted on the endothelial cells of the arterial wall by the flowing blood. Blood flow may be either smooth and laminar, tending to result in moderate/physiological to high shear stress which is considered atheroprotective, or it can be disturbed, characterised by areas of flow reversal, resulting in low endothelial shear stress and this is where the atherosclerotic plaques tend to develop [17] . NO provides a critical link between endothelial shear stress and endothelial dysfunction as increased fluid shear stress is one of the triggers resulting in the activation of eNOS and, as outlined above, subsequent NO synthesis [14] . A reduction in NO bioavailability due to oxidative stress is thus catastrophic for these susceptible sites in the vasculature, already characterised by lower NO production, and the consequent endothelial dysfunction constitutes the initial step of atherosclerotic plaque formation. This is followed by the infiltration and trapping of circulating lipoprotein particles in the subendothelial space, leucocyte recruitment into the intima and subsequent differentiation into macrophages and finally lipid-filled foam cells -the hallmark of the atherosclerotic plaque [18] .
Known cardiovascular risk factors all seem to contribute to the development of endothelial dysfunction, with oxidative stress emerging as a common underlying mechanism [4] . Similarly, both HIV-1 infection and its treatment have been linked to endothelial dysfunction, with oxidative stress branded the apparent culprit [19] . Dirajlal-Fargo et al. [20] found perinatally infected HIV-positive youth to have higher levels of endothelial dysfunction and immune activation when compared to their behaviourally infected counterparts, possibly due to a longer cumulative duration of HIV infection. These researchers indicate that multiple factors, including metabolic factors, inflammation and ART regimen, contribute to the progression of vascular disease in HIV-infected youth. In addition, although beyond the scope of this review, dyslipidaemia and impaired cholesterol metabolism, which are both possibly fuelled by HIV and HAART, enhance the pathogenesis of atherosclerosis as well [9, 21] . In the following sections, the association of HIV with endothelial dysfunction will be explored, both as a consequence of the virus itself and as a sideeffect of ART.
HIV-1 and endothelial dysfunction
Whether or not HIV-1 actively infects vascular endothelial cells in vivo has been described as controversial [5] . Some reviewers argue that cells are indeed directly infected [19] , whereas others are more cautious in this regard [22] . What is certain, however, is that the vascular endothelium of an HIV-1-infected individual is constantly exposed to a variety of stimuli -of viral origin and consequent to HAART -some of which have damaging downstream effects [5, 19] . Central to these downstream consequences seems to be a decrease in NO bioavailability, possibly due to increased ROS generation, which, via multiple mechanisms, steers the vascular endothelium into a dysfunctional state (Fig. 1) .
HIV-1 proteins and endothelial dysfunction
The HIV-1 genome contains nine main genes: Gag encodes for three structural proteins, pol encodes for three enzymes, env encodes for two envelope proteins, tat and rev encode for the regulatory proteins and vpu, vpr, vif and nef encode for accessory proteins (Fig. 2 ) [5, 23] . The three structural proteins include matrix proteins, capsid proteins and nucleocapsid proteins. The matrix is located between the virus envelope and the capsid, a cone-shaped structure at the centre of the mature virion, that encapsidates the viral RNA, enzymes and the nucleocapsid proteins [23] . The three enzymes, encoded by pol, are essential for the synthesis of the viral proteins and they include reverse transcriptase, which enables the transcription of single-stranded viral RNA into double-stranded provisional DNA that can be integrated into the host cell genome by integrase. Protease eventually cleaves the resultant translated viral precursor proteins, produced by host cell machinery, into mature proteins. The remaining proteins perform various accessory and regulatory functions [23] [24] [25] . HIV-1 proteins, independent of HAART treatment or HIV infection, have been associated with endothelial dysfunction and the vascular remodelling characteristic of atherosclerosis. In isometric tension studies performed on HIV-transgenic mouse aortic rings (a noninfectious model containing the genetic sequences for env, tat, nef, rev, vif, vpr and vpu, but lacking the genes for gag and pol consequently rendering it unable to replicate) significant endothelial dysfunction was observed [26] . A large proportion of HIV proteins appear to interfere with endothelial cell signalling, driving cellular processes down inappropriate pathways, thus disturbing homoeostasis. [29] ↑oxidative stress h [28] ↑VCAM-1 e [29] ↑ICAM-1 a [30] ↓claudin-1 h [31] ↓claudin-5 h [31] ↓ZO-2 h [31] ↓occludin f [32] ↑apoptosis g [35] ↑oxidative stress h [28] ↓eNOS d [38] Nef Vpu Vpr ↑ROS d,e,i [41, 42] ↑oxidative stress e,i [42] ↓eNOS e,i [42] ↑MCP-1
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Tat
Human immunodeficiency virus-1 Tat, trans-activator of viral replication, enhances viral transcription and replication, which means that it is able to enter the host cell's nucleus. It can also be secreted by infected cells in the absence of cell lysis and imported by various target cells, including endothelial cells [27] . Tat has been linked to many of the characteristics of endothelial dysfunction, such as enhanced ROS production, increased endothelial cell permeability and adhesion molecule expression.
In rat brain endothelial cells, exposure to Tat caused a significant increase in oxidative stress [28] . Tat's ability to induce ROS production was found to be associated with the activation of the transcription factor, nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB), in human pulmonary artery endothelial cells. In these cells, Tat exposure induced the expression of vascular cell adhesion molecule 1 (VCAM-1), which the researchers speculated might be mediated by ROS production, p38 mitogen-activated protein kinase (MAPK) activation and the nuclear translocation of NFKB [29] . Treatment of human umbilical vein endothelial cells with Tat caused monocyte adhesion via increased intercellular adhesion molecule 1 (ICAM-1) expression, where activation of the MAPK pathways also resulted in NFKB nuclear translocation which ultimately led to the increased ICAM-1 [30] . The HIV virion is enclosed by a virus envelope studded with Gp160 proteins. Gp160 comprises two associated envelope proteins, Gp120, a surface glycoprotein, and Gp41, a transmembrane component. The matrix is located between the virus envelope and the capsid, which contains the viral RNA, enzymes and nucleocapsid proteins (Illustration: Neeske Alexander).
Tat has been shown to increase the permeability of brain endothelial cells via alterations in tight junction proteins. It decreased the expression of claudin-1, claudin-5 and zonula occludens-2 (ZO-2) in cultured brain endothelial cells [31] as well as occludin mRNA and protein levels -by both inhibiting occludin's expression and cleaving it via matrix metalloproteinase-9 [32] . Tat in combination with pro-atherogenic shear stress were shown to act synergistically to increase endothelial cell expression of cathepsin K, a protease which has been associated with coronary artery disease [33] , in HIV-transgenic mice and cultured human aortic endothelial cells [34] . Furthermore, Tat was found to cause apoptosis in primary human lung microvascular endothelial cells via caspase-3 activation, following a pathway distinct from the traditional Fas-ligand or TNF pro-apoptotic pathways [35] .
In addition, HIV-1 Tat can also exert its effects on endothelial functioning in an indirect manner. In human monocytes, it can lead to the activation of protein kinase C, MAP kinase, and NFKB signalling, inducing the production of tumour necrosis factor alpha (TNF-a) [36] , which, as will be discussed in the following section, is also involved in endothelial dysfunction.
Gp160
Gp160 comprises the two associated envelope proteins Gp120 and Gp41 (Fig. 2) . Gp120 is a glycoprotein expressed on the surface of HIV virions as well as on infected host cells and the Gp41 component is a transmembrane protein. These viral proteins interact with CD4 and chemokine receptors on host cells enabling HIV to enter and infect the cell [5, 23] . Like Tat, Gp160 has been linked to endothelial dysfunction, with reduced eNOS levels, increased oxidative stress and increased endothelial barrier permeability all implicated [28, [37] [38] [39] .
In porcine coronary artery rings, Gp120 exposure after TNF-a pretreatment significantly decreased endothelium-dependent vasorelaxation compared to untreated controls. TNF-a pretreatment and subsequent Gp120 exposure also significantly reduced eNOS mRNA levels and protein expression in the porcine coronary rings as well as in cultured human coronary artery endothelial cells [38] . In rat brain endothelial cells exposure to Gp120 caused a significant increase in oxidative stress [28] .
In human brain microvascular endothelial cells, Gp120 was shown to up-regulate interleukin-6 (IL-6) and interleukin-8 (IL-8) expression, which enhanced the adhesion and migration of monocytes across in vitro blood brain barrier models [37] . It was also shown to activate protein kinase C, resulting in intracellular calcium release, which led to cytoskeletal alterations, including the disruption of tight junctions, ultimately decreasing blood brain barrier tightness and thus increasing monocyte migration across the barrier [39] .
Nef
Human immunodeficiency virus-1 negative factor, Nef, is involved in the downregulation of certain cellular receptors, including CD4, MHCI, MHCII and CD28 [40] . The downregulation of MHC I is thought to protect HIV-infected cells from the host's cytotoxic T cell response, whereas CD4 down-regulation likely limits the adhesion of HIV-infected T cells to antigenpresenting cells, safeguarding the movement of these infected cells into the circulation and thus the spread of the virus. Another explanation for CD4 downregulation is that it ensures that there is no interaction between CD4 receptors of the already infected cell and the Gp160 proteins of new virions budding from it. CD4 downregulation therefore contributes to Nef's role in enhancing viral infectivity. Furthermore, Nef interferes with host cell signal transduction as well as the regulation of cholesterol trafficking [40] . Although the mechanism remains to be elucidated, Nef has the ability to enter endothelial cells with deleterious consequences, including atherosclerotic chemokine release, ROS formation, mitochondrial dysfunction and apoptosis [41, 42] . Wang et al. [41] demonstrated that Nef could independently induce its own transfer from Jurkat T cell and THP1 monocyte cell lines to cultured human coronary artery endothelial cells via a mechanism involving direct cell to cell contact. Nef was moreover shown to induce endothelial activation, dysfunction and apoptosis, which occurred by means of an NADPH oxidase and ROS-dependent mechanism. In addition to ROS-generation and apoptosis, exposure of endothelial cells to Nef resulted in the release of monocyte chemoattractant protein-1 (MCP-1) in an NFKB dependent manner.
After incubation with solutions supplemented with various concentrations of Nef for 24 hours, porcine pulmonary artery rings showed a significant decrease in endothelium-dependent vasorelaxation. Furthermore, Nef resulted in a significant increase in superoxide production in cultured human pulmonary artery endothelial cells (HPAECs) as well as porcine pulmonary arteries, leading to increased oxidative stress. Nef exposure reduced eNOS expression in cultured porcine pulmonary artery endothelial cells and HPAECs [42] . In two mouse models of atherosclerosis, injected recombinant Nef resulted in dyslipidaemia and the accumulation of cholesterol within macrophages in the animals' vessel walls [43] . In the light of the above, Nef clearly contributes to the development of endothelial dysfunction, which can ultimately culminate in atherosclerosis.
Vpu and Vpr
Viral Protein U is a membrane protein that, similar to Nef, induces the degradation of the CD4 receptor in HIV-infected lymphocytes and, additionally, it is able to form ion channels in cell membranes. Via these mechanisms, Vpu counteracts host cell factors that hamper the release of progeny virions from infected cells. In this way, Vpu acts as an antagonist to the host's innate immune response in HIV infection [40, 44] . For instance, in lymphocytic cell lines, it has been shown that an increase in the mRNA expression of ICAM-1 observed in these cells when infected with HIV-1 is counteracted by Vpu through the downregulation of ICAM-1 from the cell surface. This results in a decrease in the formation of conjugates between infected CD4-positive T cells and NK cells and consequently a reduction in the NK cell-mediated killing of HIV-infected T cells [45] . Viral Protein R is involved in the nuclear import of proviral DNA, where it is known to interfere with host cell cycle progression and can induce apoptosis [40] . Very little is known about the endothelial effects of Vpu and Vpr. In an in vitro setting where cultured human umbilical vein endothelial cells were infected with recombinant adenoviruses that expressed individual HIV-proteins, cultured Blymphocyte cells adhered exclusively to Vpu-expressing endothelial cells. This was attributed to the ability of Vpu to upregulate endothelial CD40, which in turn resulted in the efficient expression of VCAM-1 [46] . Vpr treatment induced apoptosis in primary human brain microvascular endothelial cells, an effect that was synergistically enhanced by cotreatment with ethanol [47] .
HIV-1-induced proinflammatory cytokines and endothelial dysfunction
Most nucleated cells are able to synthesise and respond to cytokines and, proinflammatory variants such as interleukin-1b (IL-1b), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a), promote inflammation [48, 49] . Cytokines are, however, primarily produced by lymphocytes and macrophages in response to toxins, injury or inflammatory mediators [50] . HIV infection is characterised by a sustained state of immune activation, which persists even in the presence of HAART [51] . Compared to HIV-negative men, HIV-positive men were shown to have significantly higher blood levels of biomarkers of inflammation, including IL-6, ICAM-1 and soluble TNFa receptor I and II [52] . The sustained inflammation present in HIV infection has been ascribed to ongoing viral replication; coinfections (most notably other chronic viral infections); the translocation of microbial by-products across a dysfunctional gut mucosa; the loss of immunoregulatory cells and damage to immune structures [53, 54] . Furthermore, the viral proteins themselves have been shown to prompt the production of inflammatory cytokines in host cells [36, 37] Inflammation has emerged as a key mechanism responsible for the high prevalence of CVD in the HIV-infected population [51] . Proinflammatory cytokines promote the inflammation-dependent activation of endothelial cells causing an increase in adhesion molecule expression with subsequent monocyte adherence, increased vascular permeability, and elevated ROS production contributing to the development of endothelial dysfunction ( Fig. 1) [50, 55] .
The effects of HIV-1 infection on cytokine production are extensive. The virus decreases the production of some cytokines, while increasing the production of others, thus, dysregulating cytokine homoeostasis [12] . Due to the large amount of data available on this topic, it was decided, for the purposes of this review, to limit our search to cytokines that have traditionally been described as proinflammatory [48, 56, 57] and most commonly thought to be up-regulated in the context of HIV infection [12, 56, 58] . Therefore, the focus will be on TNF-a, IL-1b and IL-6.
Tumour necrosis factor-alpha
Vascular endothelial cells are regarded as the primary targets of TNF-a [59] and this proinflammatory cytokine has been implicated in their dysfunction. Previous studies conducted in our laboratory showed that short term in vitro TNF-a treatment resulted in rat cardiac endothelial cell dysfunction as demonstrated by the attenuation of the eNOS-NO biosynthesis pathway and increased oxidative stress [60] . Other in vitro and animal-based studies have also pointed to TNF-a in a reduction in NO bioavailability, and thus subsequent endothelial dysfunction [61, 62] . Upon binding to its receptor, TNF-a prompts the translocation of NFKB form the cytosol to the nucleus, where it elicits the transcription of a number of proinflammatory genes including TNF-a itself, perpetuating the inflammatory state, and the adhesion molecules VCAM-1 and ICAM-1, promoting leucocyte adhesion. While TNF-a and IL-1b both resulted in an increase in VCAM-1 and ICAM-1 in human cerebral microvascular endothelial cells, TNF-a induced a considerably higher level of expression [63] . Besides TNF-a, NFKB can also be activated by several agonists such as oxidised low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), glucose and viral infection [16] . NFKB activation thus emerges as a common pathway induced by many of the known contributors to CVD.
Several human studies have demonstrated that HIV infection is associated with increased TNF-a. From the early stages of HIV-1 infection, serum levels of TNF-a seem to be elevated [64] . In HIV-infected women, augmented TNF-a levels persisted even after antiretroviral treatment was initiated and circulating HIV RNA was below the detectable limit [65] . TNFa was also independently associated with increased internal carotid artery intima-media thickness (IMT), a subclinical marker of atherosclerosis, in HIV-positive subjects [66] . Since findings from in vitro studies have demonstrated a direct contribution of TNF-a to decreased NO levels in endothelial cells, TNF-a may also be a candidate causal agent in HIV-associated endothelial dysfunction. Indeed, an in vitro investigation by Jiang et al. (2010) identified synergistic effects of TNF-a with HIV-1 proteins. They showed that pretreatment of porcine coronary arteries and human coronary artery endothelial cells with TNF-a resulted in substantially increased endothelial ICAM-1 expression and a significant downregulation of eNOS when these cells were subsequently treated with the HIVrelated protein, Gp120. However, overall there is a paucity of in vitro studies on the direct endothelial cellular effects of TNF-a in the context of HIV, warranting further investigations into the mechanisms linking this co-occurrence with endothelial dysfunction.
Interleukin-1b and Interleukin-6
Interleukin-1b can be regarded as the apical proinflammatory cytokine. It is a multifunctional protein with downstream effects that include the translocation of NFKB to the nucleus and, as with TNF-a, elicits the transcription of a host of proinflammatory genes [67] . Activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome results in the cleavage of pro-interleukin (IL)-1b into active IL-1b, which exerts further downstream effects on IL-6 and c-reactive protein (CRP) production. Both IL-1b and IL-6 have been linked to increased vascular inflammation, endothelial dysfunction and atherosclerosis [68] .
Human immunodeficiency virus-1 infection was found to induce IL-1b production in human monocytes [69] and although there is limited data available on IL-1b and its direct effects on endothelial function in the context of HIV, this inflammatory cytokine has been linked to increased adhesion molecule expression. In human cerebral microvascular endothelial cells IL1b resulted in an increase in ICAM-1 and VCAM-1 [63] and in human umbilical vein endothelial cells IL1b activated ICAM-1 and E-selectin as well as the inflammatory mediators MCP-1 and NFjB [70] . From the available knowledge, it could thus be speculated that the increase in IL-1b production associated with HIV plays a part in the endothelial dysfunction related to this virus. However, more basic research, especially in the context of HIV, is needed to add substance to this supposition.
Interleukin-1b levels chiefly drive IL-6 signalling and IL-6 predominantly functions as a secondary signalling cytokine, exacting its effects on CRP [68] . CRP, together with most acute-phase proteins, is present during both acute and chronic inflammation and it contributes to many of the pathophysiologic effects in the inflammatory process, including the recognition of foreign pathogens and damaged cells, activating the complement system and inducing inflammatory cytokines' release from monocytes, to name a few [71] . In humans, IL-6 is strongly associated with an increase in all-cause mortality in HIV-positive individuals [72, 73] and both IL-6 and CRP have been linked to an increase in cardiovascular risk in this population independent of other cardiovascular risk factors [74] . Moreover, a meta-analysis by Howren et al. [75] noted that depression was linked to IL-6 and CRP in patients with CVD. Most human studies report CRP levels when investigating systemic inflammation as it is the more commonly used inflammatory marker. CRP has been associated with atherosclerosis in both HIVpositive and control group subjects, with a positive correlation noted between serum CRP levels and common carotid and internal carotid artery IMT [66] . In an international study of almost 10 000 HIV-infected persons, higher HIV RNA levels correlated with higher IL-6 levels, and higher nadir CD4 positive cell counts were associated with lower IL-6 levels [76] . In 149 HIV-infected individuals receiving ART with undetectable viral loads, higher monocyte C-C chemokine receptor type 5 (CCR5) expression and plasma IL-6 levels were associated with atherosclerosis independent of traditional cardiovascular risk factors. Furthermore, increased plasma IL-6 and carotid IMT were individually associated with all-cause mortality [77] . In patients with ST-elevation acute myocardial infarction treated by successful percutaneous coronary intervention (PCI), local IL-6 levels positively predicted for microvascular dysfunction [78] .
With regard to in vitro studies investigating their direct endothelial cell effects, both IL-6 and CRP have been shown to exact consequences associated with endothelial dysfunction. CRP has been linked to increased adhesion molecule expression [79] in endothelial cells as well as reduced NO bioavailability via a mechanism that involves decreased eNOS expression [80, 81] . In human umbilical vein endothelial cells, IL-6 resulted in increased endothelial permeability in a dose-and time-dependent manner. These changes were linked to a rearrangement of the tight junction protein, zonula occludens-1 (ZO-1) and cytoskeletal actin [82] . Alsaffar et al. [83] demonstrated that IL-6 promotes an increase in endothelial monolayer permeability which lasts over 24 hours. However, they speculated that the changes observed in the localisation of the tight junction molecules VE-cadherin and ZO-1 were not the cause of the increased permeability, since these changes were only evident several hours after the maximal IL-6 response (which occurred at 6 hours post treatment). This suggests that while the events were a consequence of the IL-6 signalling pathway, they were not the cause of the initial increase in permeability.
The above results provide a possible explanation for the associations between IL-6/CRP as well as IL-1b and CVD in HIV, with endothelial dysfunction appearing as the point of convergence. However, there is paucity in the data available on the direct endothelial cellular effects of these proinflammatory cytokines, especially in the context of HIV, and more basic research is needed to elucidate the mechanisms involved.
Antiretroviral therapy and endothelial dysfunction
Antiretroviral drugs block HIV replication at various stages in the virus life-cycle and are accordingly divided into five classes (for an overview of the drugs and drug classes see Maartens et al. [22] ). Highly active antiretroviral therapy (HAART), where a cocktail of these drugs, most often combining Nucleoside-analogue Reverse Transcriptase Inhibitors (NRTIs) and/or NonNucleoside Reverse Transcriptase Inhibitors (NNRTIs) with Protease Inhibitors (PIs), are given to patients, has been linked to lipodystrophy, dyslipidaemia, direct mitochondrial DNA damage as well as insulin resistance -all risk factors for atherosclerotic cardiovascular disease [19] . In the 'Data Collection on Adverse Events of Anti-HIV Drugs (DAD)' study, a large, ongoing cohort study of HIV-positive participants on treatment, a significant association was noted between the duration of exposure to ART and the risk of myocardial infarction. The findings furthermore suggest that the risk varies according to the ART drug class, with especially PIs contributing to a significant increase in myocardial infarction risk. However, the researchers speculated that this might partly be a consequence of the adverse effects of the drugs on serum lipids [84] . PIs have also been linked to higher IL-6 levels, compared to efavirenz [76] . The extent of the observed cardiovascular risk associated with ART has burgeoned to a point where there is now controversy regarding whether living with HIV or being on ART presents a greater cardiovascular threat [85] .
In the light of the many cardiovascular and other adverse effects of ART, a CD4-positive T-cell countguided use of these drugs, as opposed to lifelong continuous use, has been proposed. This was investigated by the 'Strategies for Management of AntiRetroviral Therapy (SMART)' trial, yet, contrary to expectations, they noted an increase in the rate of adverse cardiovascular events associated with the interruption of antiretroviral therapy, albeit with borderline statistical significance. Changes in serum lipids were less favourable in participants using CD4-positive T-cell countguided ART, which might have, in part, accounted for the observed increase in cardiovascular risk in this treatment group [86] .
Since endothelial dysfunction is widely regarded as an early hallmark of atherogenesis and subsequent CVD, it comes as little surprise that it is also implicated as a putative link between ART and cardiovascular risk (Fig. 1 ). Yet, there have been some discrepancies in this regard. In HIV-positive human participants who were either treatment na€ ıve or had not used ART for at least 6 months, ART seemed to lower asymmetric dimethylarginine (ADMA) levels -a novel marker of endothelial dysfunction [87] ; in addition, Francisci et al. [88] showed that the levels of several biomarkers of vascular inflammation (sVCAM-1, MCP-1 and von Willebrand factor) were lowered by short-term HAART. In our laboratory, treatment with a fixed-dose combination of Emtricitabine-TenofovirEfavirenz improved vascular function in the aortas of rats, which was associated with increased eNOS expression [89] . In 2013, the WHO published new recommendations on first-line ART regimens [90] . According to these guidelines, it is strongly recommended that first-line ART be initiated as a fixed-dose combination (FDC) consisting of two NRTIs, Tenofovir (TDF) plus Lamivudine (3TC) or Emtricitabine (FTC), and one NNRTI, Efavirenz (EFV). Subsequently, the use of FDC regimens has gained popularity in many countries, including South Africa, which manages the world's largest Government ART roll-out programme. Once-daily FDC, due to smaller pill burdens and less frequent dosing, imparts a considerable decrease in regimen complexity, which, together with the enhanced drug tolerability of contemporary regimens, has been shown to allow for improved initial ART regimen durability [91] . According to the WHO recommendations, second-line ART should comprise two NRTIs as well as a ritonavirboosted protease inhibitor such as Lopinavir (LPV/r). Components of both first-and second-line FDC treatments have been associated with endothelial dysfunction. Given the contrasting findings on the endothelial effects of ART from previous studies, a closer examination of the mechanisms involved is warranted considering the sheer scope of FDC roll-out programmes globally. For the purposes of this review, the following commonly used ART drugs, will be discussed: TDF, FTC and EFV, as well as Lopinavir and Ritonavir.
Tenofovir, Emtricitabine and Efavirenz
With regards to endothelial effects, the NNRTI, EFV, is the most widely researched drug in the reverse transcriptase class and an association with impaired endothelial function has been shown in humans [92] and rats [93] . In an in vitro study of human coronary artery endothelial cells, EFV significantly increased monolayer permeability, which researchers ascribed to decreased expression of the tight junction proteins ZO-1, claudin-1, occludin and JAM-1 -effects mediated by increased ROS generation and the activation of JNK and NFKB [94] . In mice and in human cerebral microvascular endothelial cells, EFV was shown to affect endothelial integrity, where exposure to the drug led to decreased levels of the tight junction protein, claudin-5, and increased endothelial permeability [95] . In human umbilical vein endothelial cells, treatment with EFV resulted in an increase in ROS, which was additionally associated with the induction of heat-shock proteins, endoplasmic reticulum stress as well as autophagy [96] . In brain microvessels of HIV transgenic mice receiving continuous EFV treatment, endothelial cells displayed endoplasmic reticulum (ER) stress associated with a reduction in autophagy; these phenomena were also detected in human blood brain barrier cells, including cultured cerebral microvascular endothelial cells. These findings were somewhat unexpected as the induction of ER stress is generally associated with an increase in autophagic activity [97] . Bearing the aforementioned effects on blood brain barrier cells in mind, it may not be surprising that long-term EFV use was associated with poorer neurocognitive outcomes compared to LPV/r in a retrospective cohort study of 445 HIV-positive patients [98] . In a study researching the effects of Atripla Ò , a FDC antiretroviral drug consisting of TDF, FTC and EFV, the EFV component and not TDF or FTC, was found to be associated with increased oxidative stress and PARP, a DNA repair enzyme, activity in cultured endothelial cells as well as increased apoptosis and necrosis. In the same study, EFV also promoted impaired endothelium-derived function in rat aortic rings [93] .
The antiviral activity of acyclic nucleoside phosphonates, which includes TDF, was discovered in the 1980s by Anton ın Hol y and Erik De Clercq [99] and although not as well researched as EFV, current evidence suggests that TDF is not associated with endothelial dysfunction. FTC has also not been linked to notable vascular consequences. When human umbilical vein endothelial cells and leucocytes were treated with TDF and FTC in vitro, both in combination and separately, no changes were observed in leucocyteendothelial cell interactions [100] . Kim et al. [101] found no evidence of any direct in vitro effects by TDF on the gene transcription and expression of proinflammatory, pro-oxidative stress or pro-apoptotic genes in human coronary artery endothelial cells.
Lopinavir and Ritonavir
Of the protease inhibitors recommended for second-line ART by the WHO, Ritonavir has been most directly associated with endothelial dysfunction, and our search was unable to identify studies investigating the endothelial effects of Lopinavir in isolation. When the effects of several HIV protease inhibitors on porcine coronary arteries were investigated, significant vasomotor dysfunction, decreased eNOS expression and increased superoxide anion production were observed, with Ritonavir exhibiting the more potent effects [102] . Ritonavir has been found to cause impaired endothelial function through a reduction in eNOS expression and enhancement of oxidative stress levels in porcine pulmonary arteries and human pulmonary artery endothelial cells. In the porcine pulmonary artery rings, Ritonavir significantly reduced contraction and endothelium-dependent relaxation in a concentrationdependent manner. A significant reduction in eNOS mRNA and protein levels was observed in cultured human pulmonary artery endothelial cells subsequent to Ritonavir treatment [103] . Ritonavir-boosted protease inhibitors have been shown to induce vascular endothelial cell dysfunction, ROS production, inflammation and senescence to varying degrees in human coronary artery endothelial cells, with the strongest effects detected in cells treated with Lopinavir boosted with Ritonavir (LPV/r). Both eNOS expression and NO production were decreased by LPV/r, while endothelin-1 (an endothelium-derived vasoconstrictor) expression was increased. Furthermore, the secretion of soluble ICAM or soluble VCAM (indicative of altered cell integrity) was increased~2-3 fold by LPV/r [104] . However, contrary to the above in vitro studies, a study investigating the effects of LPV/r in healthy, nonobese human subjects, failed to show evidence of endothelial dysfunction [105] .
Apart from the direct effects of Ritonavir on endothelial cells, the drug can potentially also contribute to endothelial dysfunction in a more indirect manner as it has additionally been associated with serum lipid changes, a known risk factor for the development of endothelial dysfunction. In a cohort of HIV-negative human subjects, 100 mg of Ritonavir taken twice daily significantly increased total cholesterol, LDL cholesterol, total cholesterol/high-density lipoprotein (HDL) cholesterol ratio and triglycerides and reduced HDL cholesterol in the participants [106] . In a human study conducted in Ethiopia, Gleason et al. [107] suggested that current EFV and LopinavirRitonavir treatment regimens may play a role in the development of HIV-associated preclinical atherosclerosis as these subjects exhibited elevated cholesterol, total cholesterol/HDL cholesterol ratio and triglycerides as well as elevated markers of inflammation.
Conclusion
Attributing the disproportionately high incidence of CVD in the HIV-positive population to a single cause is not possible. This is clearly a multifaceted phenomenon encompassing a complex interplay of direct and indirect factors. Yet, endothelial dysfunction appears to be a common underlying factor, emphasising the overwhelming importance of the role played by this homoeostasis-regulating organ in health and disease. In this paper, we reviewed the extant in vitro evidence on the direct endothelial effects of the human immunodeficiency virus and its treatment, focussing on HIV-1 proteins, HIV-induced proinflammatory cytokines and common ART drugs (Table 1) . Increased ROS production and oxidative stress, linked to decreased NO bioavailability and ensuing endothelial dysfunction, have emerged as the common underlying mechanisms afflicting the vascular endothelium in the wake of HIV and ART. It is clear from the literature, however, that a significant gap still exists in terms of basic research papers providing data on the exact underlying cellular mechanisms involved in HIV-1 infection and ART. Bridging this gap could pave the way for the development of future strategies aimed at the prevention and treatment of early cardiovascular changes in PLWHA.
